Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease by Balmer, Lois A. et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
10-1-2019 
Genetic characterization of early renal changes in a novel mouse 
model of diabetic kidney disease 
Lois A. Balmer 
Edith Cowan University, l.balmer@ecu.edu.au 
Rhiannon Whiting 
Caroline Rudnicka 
Linda A. Gallo 
Karin A. Jandeleit 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
10.1016/j.kint.2019.04.031 
This is an Author's Accepted Manuscript of: Balmer, L. A., Whiting, R., Rudnicka, C., Gallo, L. A., Jandeleit, K. A., 
Chow, Y., ... Morahan, G. (2019). Genetic characterization of early renal changes in a novel mouse model of diabetic 
kidney disease. Kidney International, 96(4), 918-926. Available here 
© 2019. This manuscript version is made Available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/6678 
Authors 
Lois A. Balmer, Rhiannon Whiting, Caroline Rudnicka, Linda A. Gallo, Karin A. Jandeleit, Yan Chow, Zenia 
Chow, Kirsty L. Richardson, Josephine M. Forbes, and Grant Morahan 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/6678 
© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Basic	Research
Running	head:	Model	of	early	renal	hypertrophicy	with	diabetes
Genetic	characterization	of	early	renal	changes	in	a	novel	mouse	model	of	diabetic	kidney	disease
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Genetic	 factors	 influence	susceptibility	 to	diabetic	kidney	disease	 (DKD).	Here	we	mapped	genes	mediating	renal	hypertrophic	changes	 in	 response	 to	diabetes.	A	survey	of	15	mouse	strains	 identified	variation	 in
diabetic	kidney	hypertrophy.	Strains	with	greater	(FVB/N(FVB))	and	lesser	(C57BL/6	(B6))	responses	were	crossed	and	diabetic	F2	progeny	were	characterized.	Kidney	weights	of	diabetic	F2	mice	were	broadly	distributed.
Quantitative	trait	locus	analyses	revealed	diabetic	mice	with	kidney	weights	in	the	upper	quartile	shared	alleles	on	chromosomes	(chr)	6	and	12;	these	loci	were	designated	as	Diabetic	kidney	hypertrophy	(Dkh)-1	and	-2.	To
confirm	these	loci,	reciprocal	congenic	mice	were	generated	with	defined	FVB	chromosome	segments	on	the	B6	strain	background	(B6.Dkh1/2f)	or	vice	versa	(FVB.Dkh1/2b).	Diabetic	mice	of	the	B6.Dkh1/2f	congenic	strain
DKD	is	the	most	common	cause	of	end-stage	renal	disease	in	Western	countries	and	occurs	in	about	a	third	of	subjects	with	either	type	1	diabetes	or	type	2	diabetes	(see	the	review	by	Alsahli	and	Gerich1).
Early	 changes	 in	 the	 diabetic	 kidney	 include	 renal	 hypertrophy,	with	 a	 disproportionate	 increase	 in	 glomerular	matrix	 and	mesangial	 cell	 volume,2,3	 thickening	 of	 the	 basement	membrane	 and	 occlusion	 of	 the
glomerular	capillary	lumen,3-5	an	elevated	glomerular	filtration	rate,6,7	and	microalbuminuria.8,9
Disturbances	 in	glucose	homeostasis	drive	early	DKD	and	can	often	be	alleviated	by	strict	glycemic	control.10,11	However,	despite	 this	strong	relationship	between	hyperglycemia	and	renal	disease,	not	all
individuals	with	poorly	controlled	diabetes	proceed	to	renal	failure.	Indeed,	some	individuals	with	well-controlled	diabetes	develop	progressive	kidney	disease.12	Thus,	individual	genetic	factors	likely	play	a	role	in
determining	the	susceptibility	to	renal	disease	in	diabetes	that	is	supported	by	family	studies.13,14	Several	genome	wide	association	studies	(GWAS)	and	meta-analyses	have	been	conducted	on	various	human	populations
to	 identify	 novel	 susceptibility	 loci	 for	DKD.15,16	However,	 these	 studies’	 findings	 remain	 inconsistent,	 demonstrating	 that	 it	 is	 difficult	 to	 identify	 the	 genetic	mechanism	 involved	 in	 the	 complex	 disease	 of	DKD
(reviewed	by	Regele	et	al17),	suggesting	that	a	new	approach	could	be	useful.
Mouse	models	 have	 been	 successfully	 used	 to	 define	 genetic	 susceptibility	 to	 complex	 diseases	 such	 as	 type	 1	 diabetes,18-20	 cancer,21	 schizophrenia,22	 atherosclerosis,23	 and	 Alzheimer’s	 disease.24	 Hence
mapping	rodent	susceptibility	genes	could	help	identify	genes	that	influence	DKD	in	humans.	This	approach	was	successfully	applied	to	identify	the	genetic	locus,	Rf1,	which	confers	increased	susceptibility	to	end-
stage	renal	disease,	in	rodent	models25	and	in	African	American	individuals.26	Further	evidence	that	there	is	genetic	variability	in	kidney	disease	within	rodent	strains	includes	the	description	of	an	NZW-derived	gene
that	increases	the	risk	for	lupus-induced	glomerulonephritis,27	the	susceptibility	of	BioBreeding	(BB)	diabetes-resistant	but	not	BB	diabetes-susceptible	rats	to	renal	 lesions,28	and	development	of	renal	disease	with
obesity	and	type	2	diabetes	in	db/db,	KK,	and	New	Zealand	White	(NZO)	mice.25,29
Hyperglycemia	commonly	induces	rapid	changes	in	kidney	function	and	structure.	This	is	evidenced	from	studies	using	glucose	clamps	in	human	volunteers	where	acute	exposure	to	hyperglycemia	even	over
the	course	of	an	hour	increases	glomerular	filtration	rate.30	Furthermore,	glucose	perfusion	increases	glomerular	filtration	rate	in	kidneys	isolated	from	normal	rats.31	Glomerular	hyperfiltration	is	often	observed	in
individuals	 with	 newly	 diagnosed	 type	 1	 diabetes.32	 Significantly,	 the	 presence	 of	 hyperfiltration	 in	 early	 diabetes	 has	 been	 linked	 with	 a	 greater	 risk	 of	 the	 subsequent	 development	 of	 DKD.12,33	 Therefore,
identification	of	genes	that	regulate	the	early	kidney	responses	to	hyperglycemia	in	the	mouse	could	provide	relevant	therapeutic	targets	for	human	DKD	and	perhaps	other	complications	of	diabetes.
Results
Changes	in	kidney	weight	and	histopathology	in	response	to	diabetes
A	survey	of	15	mouse	strains	was	conducted.	Seven	days	after	the	induction	of	diabetes,	body	weight	and	kidney	weight	were	recorded	for	both	male	and	female	(diabetic)	mice.	Age-matched	nondiabetic	controls	were	also
characterized.	The	average	weight	of	both	kidneys	represented	the	wet	kidney	weight	(mg)	relative	to	the	body	weight	(g);	this	was	calculated	for	each	of	the	15	strains	(Figure	1).	The	FVB	strain	was	chosen	for	further	work	because	it
had	the	greatest	increase	in	kidney	weight	with	diabetes	(Figure	1).	Although	many	strains	exhibited	a	low	kidney	to	body	weight	score,	the	B6	mouse	was	chosen	as	the	other	progenitor	as	it	is	one	of	the	most	commonly	used	inbred
mouse	strains	and	has	well-characterized	genetics.	Kidneys	from	the	FVB	and	B6	mice	were	taken	for	histologic	analysis;	the	samples	were	blinded	and	scored	for	renal	changes	in	response	to	diabetes.34	Compared	with	the	B6	diabetic
controls	(scored	1.89	±	0.04)	(Figure	2a),	the	FVB	diabetic	kidneys	(21	days)	showed	a	marked	increase	in	glomerulosclerosis	(2.59	±	0.13;	P	<	0.0001)	(Figure	2b).	We	used	this	strain	to	characterize	the	genetic	basis	of	this	trait,	and
developed	 diabetic	 kidney	 hypertrophy,	while	 the	 reciprocal	 FVB.Dkh1/2b	 congenic	 strain	was	 protected.	 The	 chr6	 locus	 contained	 the	 candidate	 gene;	 Ark1b3,	 coding	 aldose	 reductase;	 the	 FVB	 allele	 has	 a	missense
mutation	 in	 this	 gene.	Microarray	 analysis	 identified	 differentially	 expressed	 genes	 between	 diabetic	 B6	 and	FVB	mice.	 Thus,	 since	 the	 two	 loci	 identified	 by	 quantitative	 trait	 locus	mapping	 are	 syntenic	with	 regions
identified	for	human	DKD,	the	congenic	strains	we	describe	provide	a	valuable	new	resource	to	study	DKD	and	test	agents	that	may	prevent	it.
Keywords:	alloxan;	congenic	mice;	diabetes;	diabetic	kidney	disease;	mouse	model;	quantative	trait	loci
Translational	Statement
In	this	study,	we	have	identified	genetic	loci	and	candidate	genes	that	mediate	DKD.	Other	studies	have	identified	specific	genes	that	contribute	to	early	renal	damage;	however,	there	has	not	been	any	mouse	model	that	showed	a	reciprocal	effect.	Our	work	provides	not
only	a	murine-susceptible	DKD	model	with	susceptibility	loci	identified	in	humans,	but	also	a	protected	one.	Genes	within	the	loci	can	now	be	used	as	targets	to	identify	the	mechanism	underlying	early	changes	in	DKD.	The	defined	genes	may	also	enable	personalized	care	for
patients	and	the	development	of	targeted	treatments	for	DKD	to	the	human	orthologs	of	the	loci	we	identified.
to	map	the	genes	that	were	responsible.
Characterization	of	(FVB	×	B6)	F2	generation	of	mice
The	kidney	weight	to	body	weight	ratio	(KW:BW)	in	the	(FVB	×	B6)	F2	mice	displayed	a	broad	distribution	exceeding	the	range	of	both	parental	strains	(Figure	3).	A	low-density	(approximately	10	cM)	genome-wide	scan	was
performed	by	genotyping	F2	mice	(n	=	88)	in	the	highest	and	lowest	quartiles	for	KW:BW	at	95	markers	spread	across	the	19	autosomal	chromosomes.	Logarithm	of	the	odds	(LOD)	scores	was	calculated	as	a	measure	of	linkage	at
each	marker	(Figure	4a).	From	this	scan,	we	identified	2	major	loci,	one	on	chr6	and	another	on	chr12	(Figure	4a).
Figure	1	Murine	strain	survey	of	renal	hypertrophy	in	diabetes.	Kidney	weight	was	measured	and	expressed	as	a	ratio	to	body	weight	in	both	nondiabetic	(white)	and	diabetic	(gray)	mice.	*P	<	0.05.
Figure	2	Renal	histology	of	diabetic	B6	and	FVB	mice.	FVB	diabetic	kidneys	(b)	show	a	marked	increase	in	glomerulosclerosis	compared	with	the	B6	(a).	Black	scale	bar	represents	20	μm.	To	optimize	viewing	of	this	image,	please	see	the	online	version	of	this	article
at	www.kidney-international.org.
Figure	3	The	distribution	of	wet	kidney/body	weight	(WKB)	amongst	progenitor,	F1,	and	F2	murine	populations.	B6	(n	=	20),	(FVB	×	B6)	F1	(n	=	12),	FVB	(n	=	25),	and	(FVB	×	B6)	F2	mice	(n	=	434).	The	Y	axis	represents	the	wet	kidney	weight	(mg)	normalized	to	body
weight	(g),	WKB	(mg/g).	Except	for	F1	(male	only),	male	and	female	mice	are	included,	but	not	distinguished	in	this	figure	(no	significant	differences	were	seen	between	sexes).
To	refine	these	regions,	markers	within	the	peak	intervals	were	tested	(Supplementary	Table	S1),	and	QTL	analysis	was	performed	(Figure	4b).	The	most	significant	markers	were	identified	on	chr6	at	a	position	of	86	Mbp	(LOD	=
3.55)	and	on	chr12	(LOD	=	3.88)	at	39.3	Mbp.
Analysis	 of	 the	 genotypes	 on	 chr6	 for	mice	with	 renal	 hypertrophy	 (i.e.,	 high	 KW:BW)	 in	 response	 to	 diabetes	 showed	 an	 absence	 of	 B6	 homozygotes	 at	 this	 locus,	 suggesting	 that	 the	 FVB	 allele	 dominantly	 conferred
susceptibility	to	diabetes-induced	renal	changes	(Figure	5a).	In	contrast,	mice	that	exhibited	a	low	KW:BW	ratio	had	greater	B6	homozygosity.	The	opposite	results	were	demonstrated	on	chr12,	with	none	of	the	high	KW:BW	responders
being	FVB	homozygous	and	the	low	KW:BW	mice	showing	FVB	homozygosity	(Figure	5b).	These	results	suggest	that	the	FVB	allele	at	this	locus	was	protective	(because	all	the	protected	mice	were	FVB	homozygous).	These	loci	are	here
after	referred	to	as	diabetic	kidney	hypertrophy	1	(Dkh1)	and	Dkh2,	respectively.
Test	for	gene-gene	interaction	(epistasis)
A	2-QTL	scan	was	performed	to	determine	whether	the	QTLs	interacted	additively	or	epistatically	(Figure	6).	The	Dkh1	locus	on	chr6	interacted	additively	with	Dkh2	on	chr12,	with	LOD	scores	over	7.	An	epistatic	interaction
was	observed	using	the	method	of	Carlborg	and	Haley35	between	markers	on	chr6	and	another	locus	on	chr12,	with	LOD	scores	around	3.	The	new	locus	was	associated	with	the	marker	D12Mit19	and	the	end	of	chr	12.	These	results
indicate	that	there	are	3	major	loci,	with	Dkh1	and	Dkh2	having	additive	effects	and	Dkh3	interacting	epistatically	with	Dkh1.	This	demonstrates	the	genetic	complexity	controlling	diabetes-induced	renal	changes	in	these	mice.
Figure	4	Main	effect	QTLs	for	the	kidney	weight	to	body	weight	ratio.	(a)	Logarithm	of	odds	(LOD)	scores	are	shown	at	markers	for	all	autosomes,	where	the	black	line	shows	the	P	=	0.05	threshold	for	significant	linkage,	the	red	line	represents	the	P	=	0.1	threshold	for
suggestive	linkage,	and	the	blue	line	represents	the	P	=	0.01	threshold.	(b)	Fine	mapping	of	significant	QTL	marker	positions	is	shown	for	chromosomes	6	and	12	with	marker	imputation	at	1	Mb	intervals.	The	Y	axis	represents	the	LOD	score,	the	measure	of	genetic	linkage.
Significance	threshold	denoted	by	the	95th	percentile	(P	<	0.05)	(green	line).	Arrows	indicate	peak	QTLs	in	chromosome	6	(D6Mit188,	LOD	Score	3.551)	and	chromosome	12	(D12WAD39.8,	LOD	Score	3.834).	Loci	were	deemed	significant	if	they	exceeded	the	LOD	threshold	of	3.5.
Permutation	testing	N	=	1000.
Figure	5	Genotype	data	for	chromosomes	6	(a)	and	12	(b).	Each	column	represents	individual	markers.	Each	row	represents	a	different	mouse	sample.	Genotypes	are	shown	as	colored	squares;	B6	homozygous	(blue),	heterozygous	(green);	FVB	homozygous	(red);	missing
data	(black).	KW:BW,	kidney	weight	to	body	weight	ratio.
Candidate	genes	showing	differential	gene	expression
There	are	approximately	200	genes	within	the	QTL	intervals	identified	on	chr6	and	12.	We	used	the	Sentix	BeadChip	Array	MouseRef8	to	examine	global	gene	expression	patterns	between	B6	and	FVB	diabetic	and	nondiabetic
kidneys.	Genes	were	identified	that	were	differentially	expressed	between	B6	and	FVB	kidneys	at	21-day	diabetic,	using	Illumina	DiffScore.
Within	the	QTL	regions,	16	genes	on	chr6	and	8	on	chr12	were	differentially	expressed	between	the	FVB	and	B6	diabetic	mice	at	day	21	(Table	1).	A	total	of	113	genes	were	differentially	expressed	between	FVB	nondiabetic	and
FVB	diabetic	mice	(Supplementary	Table	S2).	There	were	no	significant	changes	in	gene	expression	between	B6	diabetic	and	nondiabetic	controls.	This	suggests	that	changes	in	the	expression	of	genes	in	the	regions	that	we	identified	in
kidneys	from	diabetic	FVB	mice	were	associated	with	kidney	hypertrophy.
Table	1	Genes	within	the	candidate	regions	differentially	expressed	between	B6	and	FVB	diabetic	and	nondiabetic	mice	at	21	days	after	induction	of	diabetes
Gene	name Chromosome log2-fold	change P	value Accession	number Gene	function
MGST1 6 4.1525 0.0013 NM_019946.4 Microsomal	glutathione	S-transferase
INMT 6 3.1824 0.0005 NM_009349.1 N-methylation	of	endogenous	and
xenobiotic	compounds
SSPN 6 2.8882 0.0019 NM_010656.2 A	link	between	the	F-actin	cytoskeleton
and	the	extracellular	matrix
COL1A2 6 2.2643 0.0130 NM_007743.2 Forms	pro-alpha2	chain	of	type	I
collagen
FGFR1OP2 6 1.9604 0.0028 NM_026218.2 Protein	homodimerization	activity
H2AFJ 6 1.4490 0.0382 NM_177688.2 Involved	in	the	nucleosome	structure	of
the	chromosomal	fiber
AKR1B3 6 1.2663 0.0105 NM_009658.2 aldo/keto	reductase	superfamily
ABCC9 6 1.2420 0.0132 NM_021041.2 Sulfonylurea	receptor	2
PARP12 6 1.1947 0.0282 NM_172893.2 NAD+	ADP-ribosyltransferase	activity
ART4 6 1.0005 0.0240 NM_026639.2 Post-translational	modification
AKR1B8 6 0.9823 0.0268 NM_008012.1 aldo/keto	reductase	superfamily
TACSTD2 6 0.7366 0.0557 NM_020047.3 Encodes	a	carcinoma-associated	antigen
KRAS 6 −1.2616 0.0118 NM_021284.4 Proto-oncogene
Figure	6	Interactive	QTL	analyses	of	mouse	chromosomes	6	and	12.	Additive	interactions	are	shown	above	the	diagonal.	Epistatic	interactions	are	represented	below	the	diagonal.	Chromosomes	are	shown	on	the	horizontal	and	vertical	axes.	Significant	thresholds	are
indicated	in	red	on	the	heat	map	(scale	at	the	right).	Additive	and	epistatic	logarithm	of	odds	(LOD)	scores	were	significant	if	they	exceeded	the	values	of	7	and	3,	respectively.
ANXA4 6 −1.3881 0.0159 NM_013471.1 Membrane-related	events	along	the
exocytotic	and	endocytotic	pathways
SLC13A4 6 −2.0417 0.0033 NM_172892.1 Transporter	activity	and	sodium:sulfate
symporter	activity
BCAT1 6 −2.0759 0.0165 NM_007532.2 Catalyzes	the	reversible	transamination
MAP4K5 12 1.3232 0.0109 NM_024275.2 Encodes	a	member	of	the
serine/threonine	protein	kinase	family
1700047I17RIK1 12 1.2245 0.0276 NM_028527.1 Uncharacterized
MBOAT2 12 1.1832 0.0165 NM_001083341.1 1-Acylglycerol-3-phosphate	O-
acyltransferase	activity
TTC15 12 −1.1545 0.0248 NM_178811.3 Affiliated	with	noncoding	RNA
BC022687 12 −1.2319 0.0211 NM_145450.3 Clathrin	binding	box	of	aftiphilin
containing	1
GREB1 12 −1.3871 0.0094 NM_015764.1 Important	role	in	hormone-responsive
tissues	and	cancer
SERPINA3H 12 −1.4869 0.0056 NM_001034870.2 Uncharacterized
SERPINA6 12 −1.8823 0.0035 NM_007618.2 Major	transport	protein	for
glucorticoids	and	progestins	in	the
blood
Of	interest	are	several	genes	on	chr	6	linked	to	DKD:	microsomal	glutathione	S-transferase	1	(Mgst1),	a	candidate	for	DKD;36	collagen	type	I	alpha	2	chain	(Col1a2),	a	key	feature	of	DKD;37	aldo-keto	reductase	family	1,	member
B8	(Akr1b8)	 functions	 in	biochemical	processes	 including	the	polyol	pathway	that	 is	 linked	to	DKD;38	and	aldo-keto	reductase	family	1,	member	B3	(Akr1b3),	which	has	been	implicated	in	the	amelioration	of	key	endpoints	 in	early
diabetic	nephropathy.	Only	1	gene	is	known	to	be	linked	to	DKD	on	chr	12,	that	is,	growth	regulation	by	estrogen	in	breast	cancer	1-like	(Greb1l),	a	gene	reported	as	a	target	of	retinoic	acid	signaling.39
Production	and	characterization	of	congenic	mice
Reciprocal	congenic	strains	were	produced	by	repeated	backcrossing,	selecting	breeders	at	each	generation	carrying	introgressed	genomic	intervals	identified	by	QTL	mapping.	These	strains	are	denoted	as	FVB.Dkh1/2f	and
B6.Dkh1/2b.	Where	the	peak	QTL	on	chr	6	was	genotyped	between	markers	D6Mit15-D6Mit138	and	the	peak	at	D6Mit188,	where	the	99th	percentile	was	between	77	and	89	Mbp.	The	corresponding	QTL	on	chr	12	was	genotyped
between	markers	D12Mit19-D12Msw11	and	the	peak	at	D12WAD39.8,	where	the	99th	percentile	was	between	37.3	and	42	Mbp.	The	QTL	on	chr	12	contains	both	Dkh2	and	Dkh3,	where	Dkh3	is	defined	by	marker	D12Mit19	and	is
encompassed	in	the	congenic	strains.	After	induction	of	diabetes,	differences	in	KW:BW	were	evident	between	these	congenic	strains	and	their	relevant	founder	strain	controls	(Figure	7).	The	B6	regions	intorgressed	to	the	FVB	strain
protected	against	diabetes-induced	increased	kidney	weight,	whereas	the	FVB	regions	bred	onto	the	B6	background	conferred	susceptibility	to	this	trait	on	the	resistant	B6	background.	These	results	confirmed	our	mapping	of	the	Dkh
QTLs	in	response	to	diabetes.
Glomerulosclerosis	index
Tissue	sections	of	nondiabetic	and	diabetic	kidneys	(at	21	days)	were	scored	blind40	and	plotted.	When	compared	with	control	counterparts,	the	diabetic	FVB	mice	had	evidence	of	glomerulosclerosis	(P	<	0.001)	(Figure	8).	The
B6.Dkh1/2f	diabetic	kidneys	also	had	a	significant	increase	in	glomerulosclerosis	compared	with	B6	diabetic	controls	(P	<	0.01)	(Figure	8).	This	congenic	strain	showed	a	degree	of	scarring	 in	the	glomeruli	 in	response	to	diabetes,
mediated	by	the	introduction	of	genes	from	the	FVB	strain.	By	contrast,	the	FVB.Dkh1/2b	strain	showed	limited	evidence	of	glomerulosclerosis	indicating	protection	mediated	by	the	genes	introduced	from	the	B6	strain.
Discussion
We	aimed	 to	 identify	genes	 responsible	 for	 the	early	 renal	 changes	 seen	 in	 response	 to	diabetes	using	a	genetic	approach.	A	 strain	 survey	determined	 that	 the	FVB	strain	had	 the	greatest	 renal	hypertrophy	 (KW:BW)	 in
response	to	diabetes,	whereas	the	B6	strain	did	not.	A	whole	genome	scan	of	F2	progeny	clearly	identified	2	major	loci	on	chromosomes	6	and	12.	Both	regions	are	orthologous	to	regions	identified	in	the	human	GoKinD	study,41	in
association	with	DKD.	The	QTL	located	on	murine	chromosome	6	has	an	orthologous	region	on	human	chromosome	7q.	Two	linkage	studies	in	humans	have	also	identified	DKD-associated	QTLs	in	this	same	region	(maximum	LOD	=
3.1).42,43	The	second	region	on	murine	chromosome	12	corresponds	to	a	region	on	human	chromosome	7p.	A	linkage	study	of	DKD	in	humans	mapped	a	DKD	QTL	into	this	region	(LOD	score	=	3.59).44
Within	the	QTL	regions	on	chromosomes	6	and	12,	there	are	approximately	200	genes.	Of	particular	interest	are	candidate	genes	that	lie	within	the	QTL	on	chromosome	6.	These	include	Akr1	members	B3,	B8,	B7,	and	D1.	Of
these	4	genes,	members	B3,	B8,	and	D1	have	known	human	orthologs.	The	most	interesting	of	these	genes	is	Akr1b3,	which	encodes	aldose	reductase	and	is	homologous	to	human	gene	AKR1B1.	Aldose	reductase	functions	in	the
polyol	pathway,	catalyzing	a	reduced	NAD	phosphate–dependent	reduction	of	sugar	aldehydes	to	corresponding	sugar	polyols	(discussed	by	Brownlee45).	Flux	of	glucose	through	the	polyol	pathway	 is	 increased	 in	cells	exposed	to
hyperglycemia	(reviewed	by	Brownlee45),	and	expression	of	aldose	reductase	is	increased	in	DKD	and	other	diabetic	complications.46,47	Studies	such	as	these	have	led	to	the	development	of	the	hypothesis	that	the	degree	of	aldose
reductase	gene	expression	may	modulate	risk	for	DKD.	Thus,	the	congenic	mice	we	developed	in	the	present	study	will	support	further	delineation	of	the	contribution	of	AKR1B1/Akr1b3	to	risk	for	DKD.
Glomerulosclerosis	is	a	feature	of	DKD	as	it	progresses	to	end-stage	kidney	disease.48	The	congenic	introduction	of	FVB	susceptibility	alleles	into	the	less	susceptible	B6	genetic	background	induced	diabetic	kidney	changes
including	glomerulosclerosis,	similar	to	that	of	the	parental	FVB	mouse,	confirming	that	this	DNA	region	was	responsible	for	the	renal	changes	identified.	By	contrast,	the	converse	congenic	strain,	with	B6	protective	alleles	introduced
to	the	high-risk	FVB	strain,	had	protected	against	signs	of	DKD.	These	congenic	strains	provide	confirmation	that	these	genomic	regions	harbor	genes	that	are	differentially	expressed	and	mediate	these	early	renal	changes	in	DKD.
Further	interrogation	of	these	mouse	lines	should	provide	a	better	understanding	of	the	underlying	molecular	basis	of	DKD	and	direct	future	studies	to	achieve	the	ultimate	goal	of	identifying	methods	to	prevent	or	better	treat	DKD.
Research	design	and	methods
Mice
Inbred	mouse	strains	(DBA/2,	129T2,	SJL,	CBA,	DBA/1,	NOR,	NZW,	AKR,	NZB,	NZO,	BALB/c)	were	obtained	from	the	specific	pathogen-free	colonies	at	the	Walter	and	Eliza	Hall	Institute	of	Medical	Research	(Melbourne,	Australia).	Strains	(NOD,
Figure	7	Characterization	of	renal	response	in	congenic	strains.	Kidney	weight	measured	by	the	kidney	to	body	weight	ratio,	showing	the	difference	between	nondiabetic	kidneys	(white)	and	diabetic	(gray).	The	introgressed	B6	genes	on	the	FVB	background	protect
against	increased	kidney	weight,	whereas	those	of	FVB	on	the	B6	background	resulted	in	an	increase	in	kidney	weight.	*P	<	0.001;	**P	<	0.01.
Figure	8	Glomerulosclerotic	index	in	nondiabetic	(white)	and	diabetic	(gray)	mice.	**P	<	0.01,	***P	<	0.001,	****P	<	0.0001	by	1-way	analysis	of	variance	and	Tukey’s	multiple	comparisons	test,	n	=	4–9	per	group.
A/J,	BALB/c,	NZO,	FVB,	and	B6)	were	obtained	from	the	Animal	Resources	Centre	(Perth,	Australia).	Both	male	and	female	mice	were	used	between	8	and	12	weeks	of	age.	Mice	consumed	an	ad	libitum	diet	of	standard	laboratory	chow	containing	(w/w)	6%
fat,	20%	protein,	74%	carbohydrate	(Barastoc,	New	South	Wales,	Australia),	and	water.	Artificial	lighting	was	maintained	to	a	12-hour	day/night	cycle	and	the	room	temperature	kept	constant	at	22	°C.
FVB/N	(FVB)	and	C57BL/6	(B6)	mice	were	mated	and	F1	mice	were	sibling-mated	to	generate	F2	progeny	(FVB	×	B6);	these	were	then	backcrossed	to	B6	mice	to	generate	a	backcross	denoted	as	(B6.Dkh1/2f)	or	backcrossed	to	FVB	mice	to
generate	a	backcross	denoted	as	(FVB.Dkh1/2b).	Each	backcross	was	selectively	bred	to	maximize	the	B6	genes	in	an	FVB	background	and	FVB	genes	in	a	B6	background	at	defined	locations	on	chromosomes	6	and	12.	Ethics	approval	was	obtained	from
the	Animal	Ethics	Committee	of	the	University	of	Western	Australia,	and	all	experimental	procedures	were	carried	out	in	accordance	with	guidelines	of	the	guide	for	the	care	and	use	of	laboratory	animals,	Eighth	edition	(2011).
Induction	for	diabetes	and	kidney	collection
At	6–8	weeks	of	age,	all	test	mice	were	treated	with	Alloxan	90	mg/kg	(Sigma-Aldrich,	Australia),	except	the	strains	NOR	and	SJL,	which	were	treated	with	80	mg/kg	alloxan,	by	tail	vein	injection.	Each	control	mouse,	matched	for	age	and	sex,
received	a	saline	injection.	Mice	were	monitored	daily	by	testing	for	urinary	glucose	and	weekly	for	blood	glucose	and	followed	for	7	or	21	days	after	 induction	of	diabetes	(10–20	mice	per	group).	Mice	were	considered	diabetic	 if	their	urine	glucose
concentration	was	higher	than	55	mmol/l	(Keto-Diabur-Test	5000,	Germany)	and	their	blood	glucose	higher	than	30	mmol/l	(Accu-Check	Performa	Roche,	Germany).	At	the	experimental	endpoints	of	day	7	or	21,	animals	were	killed	and	renal	hypertrophy
was	defined	as	the	average	kidney	to	body	weight	ratio	of	both	kidneys.	Whole	kidneys	were	weighted	and	then	placed	in	RNALater	(Ambion)	for	gene	expression	studies	or	10%	formalin	for	histology.
Genotyping
DNA	was	extracted	from	the	mouse	liver	or	from	tail	snips	as	described	previously.48	The	response	of	(FVB	×	B6)	F2	progeny	mice	(n	=	534)	to	alloxan	was	bimodal,	where	the	majority	(81%)	developed	diabetes.	A	subset	of	F2	samples	was
selected	 from	 the	434	diabetic	F2	mice.	This	 subset	 consisted	of	 the	upper	90%–100%	(2.41–2.69	mg/g	 [male	 vs.	 female])	 (n	=	44)	and	 lower	0%–10%	(1.75–2.03	mg/g	 [male	 vs.	 female])	 (n	=	 44)	 10th	 percentiles	 as	 defined	 by	 the	 change	 in	 renal
hypertrophy	amongst	diabetic	F2	mice.	Equal	numbers	of	female	and	male	mice	were	included	in	each	group.	Genotyping	was	conducted	on	samples	from	this	subset.	The	introgressed	strains	were	genotyped	for	20	generations	using	flanking	markers	on
chromosomes	6	(77–86	Mbp)	and	12	(37.3–42	Mbp)	(Supplementary	Table	S1).
The	mice	were	genotyped	by	amplification	of	simple	sequence	length	polymorphisms.	The	markers	used	in	the	polymerase	chain	reaction	assays	were	selected	from	the	JAX	website	(http://www.informatics.jax.org)	or	designed	in-house	and	named
as	chromosome	number,	Western	Australian	Diabetes	followed	by	the	chromosome	position	(Supplementary	Table	S1).	Each	of	the	markers	was	tested	for	polymorphism	between	FVB	and	B6,	using	the	following	conditions:	96	°C	for	2	minutes	and	then	35
cycles	of	96	°C	for	20	seconds,	55	°C	for	20	seconds,	and	72	°C	for	20	seconds,	followed	by	a	final	cycle	of	72	°C	for	2	minutes.	Additional	primers,	amplifying	single	nucleotide	polymorphisms	,	were	designed	for	chromosome	regions	where	there	were	no
polymorphic	microsatellite	markers.
QTL	analyses
All	genotypic	data	were	analyzed	using	J/Qtl.49	The	phenotype	investigated	was	the	natural	log	of	wet	KW	(average	of	both	left	and	right	kidney)	normalized	to	BW.	QTL	scans	for	main-effect	and	interacting	QTL	in	inbred	mice	were	performed	as
described.50	LOD	scores	were	subsequently	computed	at	2	cM	intervals	across	mouse	chromosomes	6	and	12	that	contained	significant	linkage	peaks.	Loci	were	deemed	significant	if	they	exceeded	the	LOD	threshold	of	3.5.	Significance	was	determined	by
permutation	testing	(N	=	1000).51
Microarray	analysis
RNA	was	extracted	from	diabetic	(21	days)	and	nondiabetic	kidneys	homogenized	in	Trizol	(Invitrogen)	with	the	addition	of	β-mercaptoethanol,	using	a	Precellys	BeadBeader	instrument.	RNA	was	quantified	using	a	Nanodrop	spectrophotometer
and	quality	checked	with	the	Total	RNA	Nano	6000	Assay	Kit	(Agilent)	and	the	Agilent	Bioanalyser.	All	RNA	integrity	values	were	8	or	higher.
RNA	(250	ng)	was	reversed	transcribed	using	the	Illumina	TotalPrep	RNA	amplification	Kit	(Illumina).	To	generate	the	first	strand	cDNA,	RNA	was	mixed	at	room	temperature	with	the	First	Strand	cDNA	Mix	(Illumina)	and	incubated	at	42	°C	for	2
hours.	First-strand	cDNA	synthesis	was	primed	with	a	T7	Oligo	(dT)	primer.	Post	incubation,	the	Second	Strand	cDNA	was	made	according	to	manufactures	instructions	(Illumina).
In	 vitro	 transcription	 technology	Master	Mix	 (Illumina)	 was	 added	 to	 each	 cDNA	 sample.	 Samples	were	 incubated	 at	 37	 oC	 for	 16	 hours.	 cRNA	 purification	was	 performed.	 Biotin-labeled	 antisense	 cRNA	was	 quantified	 using	 a	Nanodrop
Spectrophotometer.	cRNA	was	deemed	appropriate	for	further	use	if	the	concentration	was	200	ng/μl	or	higher.
A	total	of	750	ng	cRNA	in	5	μl	nuclease	free	water	was	prepared	after	cRNA	quantification	and	hybridized	to	Sentix	Bead	Chip	Array	MouseRef-8	(Illumina)	according	to	the	manufacturer’s	instructions.	Chip	scanning	was	conducted	using	the	Bead
Array	Scanner	(Illumina).	Microarray	expression	data	have	been	deposited	in	the	Gene	Expression	Omnibus	under	Accession	Number	GSE123677.
Data	analysis	and	statistics
Microarray	data	were	analyzed	using	Illumina	Bead	Studio.	The	data	were	first	filtered	according	to	the	detection	P	value.	Illumina	probes	were	analyzed	for	noise	and	nonspecific	binding.	Detection	P	values	were	computer	based	on	the	rank	of
the	Z	value	of	a	probe	relative	to	the	Z	values	of	the	negative	controls	(Illumina)	(with	P	value	<	0.01).
Data	were	rank-invariant	normalized	to	minimize	the	effects	of	variation	arising	from	nonbiological	factors.	FVB	diabetic	kidney	samples	were	normalized	to	B6	diabetic	samples,	and	in	a	separate	analysis,	FVB	nondiabetic	kidney	samples	were
normalized	to	FVB	diabetic	samples.	DiffScore	was	generated	to	determine	the	variable	expression	of	genes.	DiffScores	of	greater	than	13	or	less	than	−13	were	associated	with	P	<	0.05.	A	DiffScore	of	greater	than	30	or	less	than	−30	was	associated	with
P	<	0.01.
Gene	locations	were	determined	using	MGI	Batch	Query	(http://www.informatics.jax.org)	and	Entrez	Gene	function	from	the	NCBI	website	(http://ncbi.nlm.nih.gov).
Morphological	changes	in	the	diabetic	kidney
One	kidney,	at	7	or	21	days	of	diabetes,	was	transversally	cut	into	4	equal	pieces,	and	2	alternating	pieces	were	taken	for	processing	and	embedding	into	glycolmethacrylate	or	paraffin.	Blocks	were	sectioned	at	3	μm	and	stained	with	periodic	acid-
Schiff.	Glomerulosclerotic	index	was	assessed	using	a	semiquantitative	method52	in	20	glomeruli	from	the	2	alternating	pieces	at	a	magnification	of	×400.	Glomeruli	were	graded	according	to	the	severity	of	damage,	assessed	on	the	following	parameters:
mesangial	matrix	expansion	and/or	hyalinosis	of	focal	adhesions,	true	glomerular	tuft	occlusion,	sclerosis,	and	capillary	dilation.	Specifically,	grade	1	indicates	<25%	glomerular	injury;	grade	2,	26%–50%;	grade	3,	51%–75%;	and	grade	4,	>75%.
Glomerulosclerotic	index	was	calculated	using	the	following	formula:	Glomerulosclerotic	index	=	[(1	×	n1)	+	(2	×	n2)	+	(3	×	n3)	+	(4	×	n4)]/n1	+	n2	+	n3	+	n4,	where	nx	is	the	number	of	glomeruli	scored	within	each	grade	of	glomerulosclerosis.
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intervals	are	shown	in	red.	The	outermost	primers	determine	the	congenic	intervals.
Table	S2.	Differential	expression	of	genes	between	B6	and	FVB	diabetic	and	control	kidneys.	Genes	differentially	expressed	on	chromosome	6	between	diabetic	and	control	FVB	kidneys:	(i)	genes	differentially	expressed	on
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